Global Hereditary Angioedema Market Market Size
The market for hereditary angioedema was valued at US$ 2.72 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 8.4% to reach US$ 6.35 billion by 2030.
Recurrent episodes of extreme swelling, or angioedema, are the hallmarks of the uncommon illness known as hereditary angioedema (HAE). Patients experiencing hypoxic-ischemic episodes (HAEs) present with edema or swelling, primarily in the hands, feet, face, and mouth. Usually starting in childhood, HAE symptoms get worse as a person approaches puberty. Hereditary angioedema mostly manifests in one of three forms, designated type I, II, or III, depending on the patient's blood levels of a protein called a C1 inhibitor and the underlying causes of the condition. HAE comes in three primary varieties. Type III is typically the result of a mutation in the F12 (factor XII) gene, whereas types I and II are caused by a mutation in the SERPING1 gene, which produces the C1 inhibitor protein. The outcome is elevated bradykinin levels, which encourage edema. The disorder may arise as a replacement mutation or be inherited autosomally dominantly from one's parents. Attacks can be triggered by small trauma or stress, although they frequently happen without any clear prior events. Levels of C4 and C1 inhibitors are measured to make the kinds I and II diagnoses. The management of HAE includes taking steps to prevent attacks and, if attacks do occur, treating them. Supportive care, such as breathing support and intravenous fluids, may also be necessary during an attack. While ecallantide and icatibant are frequently used to treat acute attacks, C1 inhibitor medicines are frequently used for prevention and therapy.